Laurus Labs Ltd Share Price (LAURUSLABS)

Multiple Players Receive Tentative Approval for Dolutegravir 50mg Tablets - 15 Sep, 2023

Laurus Labs Ltd is one of the eight players that have received tentative approval from the USFDA to manufacture and market Dolutegravir 50mg tablets, used in treating HIV-1 infection.

Laurus Labs Acquires Stake in Laurus Bio; Stock Downgraded - 12 Sep, 2023

Laurus Labs acquires a majority stake in Laurus Bio through secondary purchase. However, Kotak Institutional Equities downgrades the stock to 'Sell' due to slow performance of ARV segment.

Sell Call on Laurus Labs - 16 Aug, 2023

Analyst advises to short Laurus Labs stock with a target of Rs 370 and stop loss at Rs 390 due to sustained selling pressure. Shares up over 8% in the last month.

Laurus Labs Reports Fall in Quarterly Profit - 14 Aug, 2023

Laurus Labs Ltd reported a decline in quarterly profit and revenue due to weak demand in its API business, resulting in core profit margins sinking to a 19-quarter low.

Analysts Provide Buy/Sell Recommendations for GAIL and Laurus Labs - 09 Aug, 2023

Kunal Bothra recommends buy/sell on GAIL and Laurus Labs, while Nooresh Merani suggests the same for GAIL and Federal Bank in today's trading session.

Laurus Labs Looks Attractive for Long-Term Investment - 07 Aug, 2023

According to market experts, Laurus Labs is an attractive long-term investment due to the high number of molecules in Phase 3 and a good size of opportunity. Newland has also performed well.

Laurus Labs Forms Bullish Structure, P/E Ratio at 23.70 Times - 04 Aug, 2023

Laurus Labs Ltd's stock has formed a bullish structure with higher top higher bottom formation and an A-B-C pattern breakout with volume confirmation. Additionally, the company's P/E ratio stands at 23.70 times.

Traders Bet on Wide Trading Range for Laurus Labs - 02 Aug, 2023

Traders are betting on a wide trading range of 30% for Laurus Labs due to its struggle to perform this year and company problems. The range for the August series is between 300-400.

Laurus Labs Shares Surge After Motilal Oswal Report - 31 Jul, 2023

Shares of Laurus Labs surged over 6% after Motilal Oswal's research report highlighted the company's lower-than-expected earnings for Q1FY24 but reiterated a BUY rating on the stock with a price target of INR410.

Retail Investors Hold Majority Stake in Laurus Labs - 29 Jul, 2023

Around 35% of Laurus Labs is owned by retail investors, giving them a significant say in management and business strategy. Insiders who own 32% came under pressure after market cap dropped to ₹182b last week.

Laurus Labs Reports Dismal Q1 Results - 28 Jul, 2023

Laurus Labs Ltd's Q1 FY24 results show an 88.8% plunge in consolidated net profit and 23.2% slide in revenues. Brokerages have a bleak outlook.

Laurus Labs' Q1 Net Profit Falls 90% - 27 Jul, 2023

Laurus Labs Ltd's Q1 net profit fell 90% YoY to Rs 25 crore, missing analysts' estimates. Shares may be impacted.

Laurus Labs Reports Strong Q1 Results and Plans to Expand Manufacturing Capacity - 13 Jul, 2023

Indian pharmaceutical company Laurus Labs beat market expectations with a 32% YoY revenue increase in Q1, driven by growth in Generics API and Synthesis business units. The company plans to expand manufacturing capacity to meet growing demand.

Laurus Labs Ltd stock has potential upside of up to 47% - 11 Jul, 2023

Laurus Labs is a pharmaceutical company that develops and manufactures APIs for various therapeutic areas. The stock has seen an improvement in score and has potential upside of up to 47%.

Laurus Labs Ltd's Debt Management Receives Positive Review - 06 Jul, 2023

Laurus Labs Limited has a low net debt to EBITDA ratio of only 1.2, and its EBIT covers its interest expense a whopping 10.9 times over. The company is managing its debt quite well.

Laurus Labs partners with IIT Kanpur for gene therapy assets - 19 Jun, 2023

Laurus Labs partners with IIT Kanpur to bring novel gene therapy assets to market, strengthening its presence in the CGT space and funding clinical trials and product launches in emerging markets.